Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Partow Kebriaei

Showing results (71-80 of 346) with videos related to

Pageof 35
Sort By:
Blood Advances|January 11, 2023
Haploidentical vs matched unrelated donors for patients with ALL: donor age matters more than donor typeRohtesh S Mehta, David Marin, Amin Alousi, et al.
Cancer Research|April 29, 2010
Combining CD19 redirection and alloanergization to generate tumor-specific human T cells for allogeneic cell therapy of B-cell malignanciesJeff K Davies, Harjeet Singh, Helen Huls, et al.
Human Gene Therapy|November 24, 2011
Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignanciesPartow Kebriaei, Helen Huls, Bipulendu Jena, et al.
American Journal of Hematology|June 11, 2013
Just-in-time rescue plerixafor in combination with chemotherapy and granulocyte-colony stimulating factor for peripheral blood progenitor cell mobilizationVeronica R Smith, Uday Popat, Stefan Ciurea, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 12, 2018
Allotransplants for Patients 65 Years or Older with High-Risk Acute Myeloid LeukemiaLauren Veltri, Katayoun Rezvani, Betul Oran, et al.
NPJ Digital Medicine|March 2, 2026
Development and explainable AI-driven characterization of a prognostic model for haploidentical transplantation outcomesRohtesh S Mehta, Yosra M Aljawai, Partow Kebriaei, et al.
Journal of Pediatric Hematology/Oncology|September 1, 2017
Etiologies and Impact of Readmission Rates in the First 180 Days After Hematopoietic Stem Cell Transplantation in Children, Adolescents, and Young AdultsOssama M Maher, Jorge G Silva, Winston W Huh, et al.
American Journal of Hematology|February 3, 2023
Younger haploidentical donor versus older matched unrelated donor for patients with AML/MDSCurtis Marcoux, David Marin, Jeremy Ramdial, et al.
American Journal of Hematology|July 4, 2020
Haploidentical transplants for patients with relapse after the first allograftSamer A Srour, Piyanuch Kongtim, Gabriela Rondon, et al.
Cancer|May 2, 2013
Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemiaHagop Kantarjian, Deborah Thomas, Jeffrey Jorgensen, et al.
Pageof 35

Showing results (71-80 of 346) with videos related to

Sort By:
Pageof 35
Blood Advances|January 11, 2023
Haploidentical vs matched unrelated donors for patients with ALL: donor age matters more than donor typeRohtesh S Mehta, David Marin, Amin Alousi, et al.
Cancer Research|April 29, 2010
Combining CD19 redirection and alloanergization to generate tumor-specific human T cells for allogeneic cell therapy of B-cell malignanciesJeff K Davies, Harjeet Singh, Helen Huls, et al.
Human Gene Therapy|November 24, 2011
Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignanciesPartow Kebriaei, Helen Huls, Bipulendu Jena, et al.
American Journal of Hematology|June 11, 2013
Just-in-time rescue plerixafor in combination with chemotherapy and granulocyte-colony stimulating factor for peripheral blood progenitor cell mobilizationVeronica R Smith, Uday Popat, Stefan Ciurea, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 12, 2018
Allotransplants for Patients 65 Years or Older with High-Risk Acute Myeloid LeukemiaLauren Veltri, Katayoun Rezvani, Betul Oran, et al.
NPJ Digital Medicine|March 2, 2026
Development and explainable AI-driven characterization of a prognostic model for haploidentical transplantation outcomesRohtesh S Mehta, Yosra M Aljawai, Partow Kebriaei, et al.
Journal of Pediatric Hematology/Oncology|September 1, 2017
Etiologies and Impact of Readmission Rates in the First 180 Days After Hematopoietic Stem Cell Transplantation in Children, Adolescents, and Young AdultsOssama M Maher, Jorge G Silva, Winston W Huh, et al.
American Journal of Hematology|February 3, 2023
Younger haploidentical donor versus older matched unrelated donor for patients with AML/MDSCurtis Marcoux, David Marin, Jeremy Ramdial, et al.
American Journal of Hematology|July 4, 2020
Haploidentical transplants for patients with relapse after the first allograftSamer A Srour, Piyanuch Kongtim, Gabriela Rondon, et al.
Cancer|May 2, 2013
Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemiaHagop Kantarjian, Deborah Thomas, Jeffrey Jorgensen, et al.
Pageof 35